DD

Business profile & competitive position

DuPont de Nemours, Inc. operates under the Basic Materials umbrella in the Chemicals industry. As a diversified chemicals company, it sells specialty materials, electronics, water, and industrial biosolutions into cyclical end markets such as semiconductors, automotive, construction, and healthcare. The numbers currently tell a mixed story about how defensible that position is. The reported 0.7% net margin and 0.3% return on equity are extremely low for a large-cap chemicals franchise. Margins that thin usually point to either heavy reinvestment, depressed pricing, elevated input costs, or a capital-intensive model that does not yet convert revenue into retained shareholder returns. A wide competitive moat would normally show up as sustainably higher margins and ROE, so on the face of these figures DuPont looks more like a business fighting through a transition than one enjoying durable pricing power. That said, the company’s recent streak of large earnings surprises and its R&D recognition in healthcare do suggest product-level differentiation; the task for analysts is to decide whether that differentiation can eventually scale into bottom-line returns.

Financial posture

DuPont’s current market capitalization is $19.2 billion, with the stock at $142.48 as of the latest snapshot. Valuation is the headline issue: the trailing P/E sits at 309.7, which is extraordinarily high for a chemicals name. That multiple only makes sense if the market is pricing in a sharp earnings recovery or a substantial re-rating of growth, because the latest reported profitability is weak. Net margin is just 0.7% and ROE is 0.3%, so each dollar of sales is barely contributing to net income. Beta is 1.08, meaning the stock has moved slightly more than the broader market and is not a defensive play. The price is also trading above its 50-day EMA of $140.06, while the RSI of 54.9 is neutral—neither oversold nor overbought. Taken together, the posture is one of a company where sentiment and forward expectations appear to be running well ahead of current reported profitability.

Macro & geopolitical exposure

Because DuPont is classified as a Basic Materials / Chemicals company, its exposures are those typical of the sector rather than tech or consumer staples. That means sensitivity to feedstock and energy prices, since many chemical processes rely on oil- and gas-derived inputs. It means sensitivity to industrial demand cycles: when construction, auto, and semiconductor capital spending slow, demand for specialty chemicals usually follows. It also means exposure to trade policy and currencies; chemicals are globally traded, and tariffs, cross-border supply-chain rules, or a stronger dollar can compress overseas revenue. Finally, and especially relevant here, the industry faces significant environmental and product-liability regulation, including litigation around PFAS and other persistent chemicals. The recent New Jersey “forever chemicals” settlement is an example of how regulatory and legal risk can crystallize into multibillion-dollar cash outflows for chemicals firms.

Recent developments

The most recent headline came on August 7, 2026, when Reuters reported that New Jersey’s $2.5 billion “forever chemicals” settlements with DuPont, 3M, and other defendants won court approval. That approval moves a major environmental liability from a negotiated agreement into the cash-flow and reserve phase, and it is worth tracking for how similar state-level cases could scale. On August 6, 2026, DuPont announced it had won an R&D 100 Award for innovation in healthcare, according to PR Newswire, reinforcing the healthcare and biotechnology angle of the portfolio. Two August 5 stories framed the valuation debate: GuruFocus asked whether DuPont was overvalued after a 3.1% rally, while Zacks highlighted that the Q2 earnings call pointed to faster second-half growth. Those last two headlines capture the tension in the stock right now—optimistic guidance versus a stretched-looking valuation.

Earnings behavior & post-earnings drift

DuPont has been one of the most reliable earnings beaters in the chemicals space over the past two years. Across the last eight reported quarters, the company has beaten estimates 8 out of 8 times—a 100% beat rate—with an average earnings surprise of 53.5%. The post-earnings drift has also been positive: the average 5-day price move after earnings across those quarters is +3.41%, classified as an “up” drift.

The last four reports show how lumpy that outperformance has been. On August 4, 2026, DuPont reported EPS of $1.88 versus a $1.76 estimate, a 6.8% surprise, and the stock rose 3.11% the next day; the five-day drift was null%. On May 5, 2026, the company posted $1.65 against $0.4881 expected, a 238% surprise, with a 1.69% next-day move and a 2.64% five-day drift. On February 10, 2026, $0.46 actual beat $0.43 expected by 7%, driving a 4.25% next-day pop and a 3.88% five-day drift. On November 6, 2025, $1.09 crushed $0.4656 by 134.1%, producing a 1.66% next-day move and a 3.7% five-day drift. The next report is scheduled for November 5, 2026, before the market open, with a consensus EPS estimate of $1.89. The combination of a perfect beat rate, large positive surprises, and positive post-report drift suggests estimates have consistently trailed the company’s actual performance, but it does not guarantee the next quarter will follow the same pattern.

For a deeper dive into the balance of risks and opportunities, consult the full institutional verdict on the ticker page, where you can compare broker estimates, valuation models, and sector-relative ratings before forming your own view.